Search research articles
Contact Us
Filters
Showing results (1-10 of 64) with videos related to
Page
of 7
Sort By:
The Lancet. Public Health
|
December 19, 2017
Cost-effectiveness estimates: the need for complete reporting
James F O'Mahony
Pharmacoeconomics
|
June 16, 2020
Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit?
James F O'Mahony
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 22, 2019
HIQA's Perspective on the Challenges Posed by Evaluations of Screening Programs: A Reply
James F O'Mahony
Pharmacoeconomics
|
July 17, 2021
Comment on Keeney et al.'s "Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening"
James F O'Mahony
Pharmacoeconomics
|
March 9, 2019
Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?
James F O'Mahony
HRB Open Research
|
October 28, 2020
Interpreting cost-effectiveness ratios in a cost-effectiveness analysis of risk-tailored prostate screening: A critique of Callender <i>et al</i>
James F O'Mahony
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
October 12, 2021
Risk Stratification in Cost-Effectiveness Analyses of Cancer Screening: Intervention Eligibility, Strategy Choice, and Optimality
James F O'Mahony
Pharmacoeconomics - Open
|
July 28, 2021
Revision of Ireland's Cost-Effectiveness Threshold: New State-Industry Drug Pricing Deal Should Adequately Reflect Opportunity Costs
James F O'Mahony
Vaccine
|
October 3, 2012
Re: cost-effectiveness of pertussis booster vaccination in the Netherlands
James F O'Mahony
Pharmacoeconomics
|
October 27, 2015
The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?
James F O'Mahony, Diarmuid Coughlan
Page
of 7
Search research articles
Search
Showing results (1-10 of 64) with videos related to
Sort By:
Page
of 7
The Lancet. Public Health
|
December 19, 2017
Cost-effectiveness estimates: the need for complete reporting
James F O'Mahony
Pharmacoeconomics
|
June 16, 2020
Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit?
James F O'Mahony
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 22, 2019
HIQA's Perspective on the Challenges Posed by Evaluations of Screening Programs: A Reply
James F O'Mahony
Pharmacoeconomics
|
July 17, 2021
Comment on Keeney et al.'s "Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening"
James F O'Mahony
Pharmacoeconomics
|
March 9, 2019
Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?
James F O'Mahony
HRB Open Research
|
October 28, 2020
Interpreting cost-effectiveness ratios in a cost-effectiveness analysis of risk-tailored prostate screening: A critique of Callender <i>et al</i>
James F O'Mahony
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
October 12, 2021
Risk Stratification in Cost-Effectiveness Analyses of Cancer Screening: Intervention Eligibility, Strategy Choice, and Optimality
James F O'Mahony
Pharmacoeconomics - Open
|
July 28, 2021
Revision of Ireland's Cost-Effectiveness Threshold: New State-Industry Drug Pricing Deal Should Adequately Reflect Opportunity Costs
James F O'Mahony
Vaccine
|
October 3, 2012
Re: cost-effectiveness of pertussis booster vaccination in the Netherlands
James F O'Mahony
Pharmacoeconomics
|
October 27, 2015
The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?
James F O'Mahony, Diarmuid Coughlan
Page
of 7